In the phase I study, a 52-year-old bladder cancer patient, enrolled in the dose escalation cohort, with metastases to the lung who had failed three prior therapies was treated with erdafitinib. This patient had tumor shrinkage of 38% (Fig. 5) with a confirmed partial response by RECIST criteria...The FGFR3–TACC3 translocation was detected in this patient's tumor sample, extending the observation that these alterations are a predictor of sensitivity to erdafitinib clinically.